![Inez de Greef-van der Sand](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Inez de Greef-van der Sand active positions
Companies | Position | Start | End |
---|---|---|---|
DegenRx BV
![]() DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Chief Executive Officer | 31/08/2020 | - |
Career history of Inez de Greef-van der Sand
Statistics
International
Netherlands | 2 |
Operational
Chief Executive Officer | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
DegenRx BV
![]() DegenRx BV BiotechnologyHealth Technology DegenRx BV is a Dutch biotech company that is focused on developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer's and Parkinson's disease. The company is based in Tilburg, Netherlands. The company aims to address the lack of drugs available to stop or slow down the progression of Alzheimer's disease, which affects about two-thirds of the 50 million people reported to suffer from dementia worldwide. One of the approaches most advanced in clinical studies is immunotherapy against amyloid beta, which DegenRx is working on. Inez de Greef-van der Sand has been the CEO of the company since 2020. | Health Technology |